Ann: Lodgement of Type C Meeting Request with US FDA, page-12

The biotech perception has changed mate, most beaten down IPOs from past 18 months have significantly recovered on ASX and TRP is no exception. TRP is in good shape to deliver significant milestones in next 12 months and adequately funded to get phase 3 completion without dilution, thus still have more room to catch up in the ASX biotech space, when perception changes holders refuse to sell and in happy to wait mode thus up move requires only thin buying mate, I see nothing wrong and the up moves in last couple of weeks I noticed to comparable ASX candidates below and TRP is still behind :-(

CU6 40%
CHM 35%
RAD 35%